Reducing Lead Dust Exposure in Older Housing

March 17, 2026 updated by: Masako Morishita, Michigan State University

Reducing Lead Dust Exposure and Childhood Blood Lead Levels in Older Housing in Michigan

The objective of this study is to assess the effectiveness of portable air filtration (PAF) for mitigating lead dust exposures and reducing childhood blood lead levels in older housing.

Study Overview

Detailed Description

In close collaboration with local health departments, this project will enroll 40 participants who (1) reside in housing built before 1970, and (2) have children under six years of age with blood lead levels (BLL) >5 μg/dL. Specific objectives include (1) assess reduction of Pb dust exposure via the intervention, (2) assess the ability of PAF to reduce childhood BLL indirectly via reductions in Pb dust exposure, and (3) develop evidence-based exposure reduction guidance for wider public use of PAF. The project team will measure Pb levels in (1) suspended dust, (2) floor dust, and (3) children's blood before the start and finish of the two-month-long intervention as well as at the midpoint.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Masako Morishita, PhD
  • Phone Number: 517-884-0463
  • Email: tomoko@msu.edu

Study Locations

    • Michigan
      • East Lansing, Michigan, United States, 48824
        • Recruiting
        • Michigan State University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • child under seven years of age with BLL >5 µg/dL,
  • child must reside in housing built before 1978, and
  • child must sleep at home during participation in the two month-long study.

Exclusion Criteria:

  • anything in child's health history that could affect the study results, or
  • any circumstance that could interfere with guardian's/parent's ability to consent and/or participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: air filtration systems
Portable air filtration units will be kept running in homes for two months.
Two portable air filtration units placed in subjects' homes (one in child's bedroom and one in living room) will be kept running for two months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in blood lead level
Time Frame: After two months at the end of the intervention
change in blood lead level (in ug/dL).
After two months at the end of the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2022

Primary Completion (Estimated)

July 31, 2026

Study Completion (Estimated)

November 30, 2026

Study Registration Dates

First Submitted

May 2, 2023

First Submitted That Met QC Criteria

March 17, 2026

First Posted (Actual)

March 20, 2026

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

March 17, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • MILTS0025-21

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Elevated Blood Lead Levels

Clinical Trials on portable air filtration systems

Subscribe